Agios Pharmaceuticals, Inc. (AGIO) Stock
Key stats
- Market cap
- $1.69B
- Price / Earnings ratio
- -4.6x
- EPS (TTM)
- -$7.01
- Volume
- Loading
- 52-week high
- $46.00
- 52-week low
- $22.24
Source: third-party data provider, as of November 7, 2026
Compare with AGIO
Recent news

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
AGIO

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AGIO

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
AGIO

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
AGIO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.93
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.79
- SMA 50
- $33.37
- Price below SMA 50
- EMA 50
- $33.43
- Price below EMA 50
- SMA 200
- $31.76
- Price below SMA 200
- EMA 200
- $31.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.81 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
AGIO

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AGIO

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
AGIO

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
AGIO

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
AGIO

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
AGIO

Agios Pharmaceuticals Q2 Earnings Call Highlights
Agios Pharmaceuticals Q2 Earnings Call Highlights
AGIO

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
AGIO

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
AGIO

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
AGIO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 33.93
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.79
- SMA 50
- $33.37
- Price below SMA 50
- EMA 50
- $33.43
- Price below EMA 50
- SMA 200
- $31.76
- Price below SMA 200
- EMA 200
- $31.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $34.00
- Average
- $44.00
- High
- $55.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -21.3 | -6.2 | ||||||||||
| 2022 | -11.3 | -3.2 | -9.6 | -27.1 | -17.4 | +16.1 | -7.7 | +19.8 | -7.6 | -5.0 | +6.2 | -4.5 |
| 2023 | +7.1 | -14.4 | -8.2 | +0.7 | +9.0 | +10.2 | -5.9 | +2.4 | -12.1 | -13.3 | +4.4 | -2.8 |
| 2024 | -0.9 | +40.8 | -9.4 | +12.6 | +8.0 | -1.6 | +7.0 | +3.2 | -0.7 | +4.6 | +32.4 | -44.2 |
| 2025 | +8.0 | +5.7 | -11.5 | +8.4 | +3.7 | +1.9 | +8.3 | +7.7 | +2.3 | +7.9 | -27.2 | -2.2 |
| 2026 | +1.0 | +7.4 | +15.9 | -18.1 | +4.4 | +32.5 | -19.0 | +10.3 | -2.8 | -5.9 | -5.6 |



